JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

FibroGen Inc

Closed

SectorHealthcare

8.28 -2.47

Overview

Share price change

24h

Current

Min

8.18

Max

8.77

Key metrics

By Trading Economics

Income

-13M

4.6M

Sales

126M

2.7M

Profit margin

169.368

Employees

225

EBITDA

77M

-14M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+192.77% upside

Market Stats

By TradingEconomics

Market Cap

28M

Previous open

10.75

Previous close

8.28

News Sentiment

By Acuity

100%

0%

364 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

FibroGen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 Feb 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 Feb 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 Feb 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 Feb 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 Feb 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 Feb 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

Peer Comparison

Price change

FibroGen Inc Forecast

Price Target

By TipRanks

192.77% upside

12 Months Forecast

Average 25.5 USD  192.77%

High 43 USD

Low 8 USD

Based on 3 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.306 / 0.33939Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

364 / 374 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$